Stephen C. Glover
Co-Founder, Chief Executive Officer, and Chairman
Mr. Glover has over 32 years of business experience in biopharmaceuticals and life sciences. Mr. Glover was formerly the Co-Founder of Coherus Biosciences where he was focused on business strategy, partnerships, product development efforts, and capitalization of the company. Prior to Coherus, he was the President of Insmed Therapeutic Proteins as well as Chief Business Officer of Insmed Incorporated. At Insmed, Mr. Glover was responsible for the creation of the biosimilar business unit and the divestiture of the business to Merck. As Chief Business Officer he led Insmed's strategic review process which resulted in the merger of Insmed and Transave. Prior to Insmed, Mr. Glover held the position of Senior Vice President and General Manager at Andrx Laboratories and Andrx Therapeutics, both divisions of Andrx Corporation. At Andrx Mr. Glover was responsible for the strategy and operation of the Andrx Labs which developed and marketed products in metabolic diseases and Men's Health, and Andrx Therapeutics which was focused on the development of new controlled release products and contract manufacturing. He earlier held multiple sales, marketing and operational roles at Hoffman LaRoche, Amgen Inc. and IMS Health. Mr. Glover has multifaceted experience in Fortune 100, start up and entrepreneurial environments. His transaction experience covers over 25 transactions totaling over $10 billion, and he serves on the Boards of PDS Biotechnology and Asclepius Lifesciences.
Nicholas A. Labella, Jr. MS, RPh
Chief Scientific Officer, Senior VP Research and Development
Mr. LaBella is an experienced pharmaceutical executive with extensive expertise and core competency that spans over 34 years in Regulatory Affairs and Clinical Operations. His background includes hands-on experience in small molecule pharmaceutical development providing corporate leadership; strategic assessments; FDA interactions; preparation, submission and approval of NDA, ANDA and IND applications; and compliance with cGMP, cGCP, and cGLP. He has successfully designed, developed and executed pharmaceutical development programs in multiple therapeutic areas leading to NDA approvals. These therapeutic areas include cardiovascular, CNS, women’s health, anti-diabetic and anti-infective products. He managed a full spectrum of R&D departments; and served both on Executive Management Teams and as a Board of Director. Management experience includes growth and operations of a CRO organization with over 200 individuals. Mr. LaBella most recently served as Chief Scientific Officer at Insmed, Inc. (merged with Transave), VP of Development and Regulatory Affairs at Cardiokine, Inc, VP of Operations, Phase IV Division at Pharmanet (previously Medex Clinical Trail Services), VP of New Drug Development at Watson Laboratories (formally Circa Pharmaceuticals, where he was VP, Director of Research and Development, Director of Regulatory Affairs, and Director of Regulatory Investigational New Drugs). Mr. LaBella began his career at Sandoz Research Institute as a Senior Project Coordination Manager, followed by Associate Director of Regulatory Affairs at Lorex Pharmaceuticals. Mr. LaBella received his Bachelor of Science in Pharmacy from the University Of Connecticut School Of Pharmacy and his Master of Science in Drug Information and Communication from Arnold and Marie Schwartz College of Pharmacy, Long Island University. Mr. LaBella is a licensed Pharmacist and has published various publications and patents.
Pablo A. Guzman, MD, FACC
Chief Medical Officer
Dr. Guzman received his Bachelor’s degree in Biology from St Peter’s University in Jersey City in 1971, his Medical Degree from the University of Puerto Rico School of Medicine in 1975, and his Interventional Cardiology Fellowship at The Johns Hopkins Hospital in Baltimore in 1980. He is Board certified in Internal Medicine (1978) and Cardiovascular Diseases (1981). He joined the staff at Johns Hopkins in 1980 and his duties included patient care, teaching, and both clinical and basic science research in the dog lab. He has over 30 articles in peer reviewed journals and many abstracts, some of them presented in national meetings including the American Heart Association and the American College of Cardiology. While at Hopkins, he became a Fellow of the American Heart Association Council on Clinical Cardiology, a member of the North American Society of Pacing and Electrophysiology, and a Fellow of The American College of Cardiology and served as the Assistant Director of the cardiac catheterization lab and Co-director of the permanent pacemaker lab and Co-director of the cardiac catheterization lab at Baltimore City Hospital (Now Francis Scott Key Hospital). Dr. Guzman practiced Medicine/Interventional Cardiology in South Florida for  years, and in 1987 Dr. Guzman designed and became the Director of the Cardiac Catheterization Lab at Boca Raton Community Hospital (now Boca Regional Hospital) and a Fellow of the Society for Cardiac Angiography and Interventions. He then became the Associate Director of the Cardiac catheterization Laboratory at North Ridge Medical Center. He is a past president of the Caducean Society of Greater Fort Lauderdale, a past Chief of the Department of Cardiovascular and Pulmonary Diseases at North Ridge Medical Center. Dr. Guzman was a managing partner of Cardiology Associates of Fort Lauderdale, and a past member of The Broward County Medical Association and sits on the Board of Trustees at Holy Cross Health, a member of Trinity Health since 2015. He sits on the Scientific Advisory Board of Campbell Neurosciences Inc. and Therapeutics Solutions International.
Chief Commercial Officer
Ms. Cashmere has more than 25 years’ experience in business planning and execution for biopharmaceutical and medical device companies ranging in size from start-up to Fortune 100 companies. She formerly led the Marketing Communications function at Mako Surgical Corporation, an emerging robotic orthopedics company, where she was responsible for creating awareness and driving sales of $1+ Million Robotic Arm Systems and implants for partial knee and total hip arthroplasty. Substantial unit sales and revenue growth during her tenure culminated in a $1.65 Billion acquisition by Stryker. Ms. Cashmere also served as Sr. Vice President, New Product Marketing at Auxilium Pharmaceuticals, an emerging pharmaceutical company focused on men’s health and orphan indications. Responsibilities included creation of the New Product Marketing Business Unit, strategic opportunity assessment, pipeline prioritization, commercial oversight of clinical development, and masterminding new product commercialization strategies. Ms. Cashmere led Auxilium’s strategic partnership review process, resulting in out-licensing European rights of a key asset with multiple indications, Xiaflex, to Pfizer. Prior to Auxilium, Ms. Cashmere was Sr. Director, Marketing at Andrx Laboratories, responsible for a newly created business unit focusing on commercialization of pipeline products for men’s health. Earlier she held strategic marketing positions at Noven, Serono, and Abbott.
Chief Financial Officer
Mr. Wolfe has spent his career in various financial roles in the financial services, specialty finance and the pharmaceutical/healthcare industries. Most recently Mr. Wolfe has spent his time cultivating start-up organizations in various healthcare entities, often dealing with complicated business models to develop a financial framework for success for many of these first of their kind businesses. Mr. Wolfe has spent the last 17 years of his career in the healthcare industry with half of that time spent at Kos Pharmaceuticals, a publicly traded, fully-integrated specialty pharmaceutical company. Mr. Wolfe assisted in guiding Kos to 27 straight quarters of meeting or exceeding Wall Street quarterly earnings estimates. Finding the most cost-effective way to run a business through the design of more efficient systems is the hallmark of his career achievements. Mr. Wolfe has his BBA from the University of Miami and his MBA from the University of Pittsburgh.